Pharma BD Deal Intelligence
Injectable generics entry delivered initial growth but manufacturing quality issues emerged
Full analysis, sources & comparables →Teva Pharmaceutical agreed to acquire Sicor for $3.4 billion, gaining Sicor's expertise in generic injectable drugs and capabilities in duplicating the wave of…
Teva acquired Sicor for $3.4B for entry into biosimilars market.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Teva acquired Sicor for $3.4B for entry into biosimilars market.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. (this deal) | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 2003 deals · Teva Pharmaceutical Industries Ltd. deals